Scinai Immunotherapeutics (SCNI) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global rights to their patented immunotherapy technologies and related know-how to an unnamed U.S. company. The agreement includes an immediate license fee, contingent milestone payments, and royalties on future net sales. This move marks a strategic step for Scinai in the development and commercialization of its licensed products.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.